Tom is an experienced scientist and manager having served a 28 year career with Amgen. He received his graduate degrees from UC Davis and UCLA and joined Amgen as a molecular biologist and protein biochemist in 1981. He cloned, sequenced, expressed, and purified many proteins and was a key scientist in the discovery and development of Neupogen, Neulasta, and Nplate. Tom also worked in process development as a scientist and director and developed or oversaw the development of many of the processes implemented at Amgen including the Neupogen process. Tom then headed the Protein Science group at Amgen, a biologics R&D team of over 300 researchers across five sites. He retired from Amgen in 2009 as VP, Protein Sciences and since then he has helped start several companies and currently consults or is a scientific advisor to more than 10 companies.
Patrick Y. Yang, Ph.D.
From 2010 to 2013, Pat served as Executive Vice President and Global Head of Technical Operations for F. Hoffmann-La Roche Ltd., where he was responsible for Roche's pharmaceutical and biotech manufacturing operations, process development, quality, regulatory, supply management, distribution, and engineering functions. Before joining Roche, Pat worked for Genentech Inc., where he most recently served as Executive Vice President of Product Operations, and was responsible for Genentech's manufacturing, engineering, process development, quality, regulatory affairs and supply chain management functions. Prior to joining Genentech, Pat worked for Merck & Co., where he held several leadership roles including Vice President of Asia/Pacific Manufacturing Operations and Vice President of Global Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. in various research, development, engineering, and manufacturing roles.
Pat currently serves on the board of directors of Tesoro Corporation, a public independent refining and marketing company, since 2010; Codexis, Inc., a public company that develops biocatalysts for the pharmaceutical and fine chemicals markets, since 2014; PharmaEssentia Corporation, a clinical-stage biotechnology company, since 2014; and Amyris, Inc., a public synthetic biology company since 2014; and previously served on the board of TaiMed, Inc. in 2007-2009; and Celladon Corporation in 2014-2015: both clinical-stage biotechnology companies. Pat earned a Bachelor of Science in engineering from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from University of Cincinnati and a Ph.D. in engineering from the Ohio State University.